诺华上调了 2024 年的财务指引，预计核心营业利润将实现高十位数增长，而销售额将实现两位数的低增长。 Novartis raises 2024 financial guidance, expecting high-teens core operating profit growth and low double-digit sales growth.
诺华公司今年第三次提高了2024年的财务预测, 预计核心营业利将有较高的成长率, 销售额将以低两位数增长. Novartis has increased its 2024 financial guidance for the third time this year, anticipating a high-teens percentage growth in core operating profit and low double-digit sales growth. 在第三季度,公司报告净销售额增长了10%,达到1282亿美元,核心营业收入增长了20%,达到5145亿美元,超过分析师的预期. In Q3, the company reported a 10% rise in net sales to $12.82 billion and a 20% increase in core operating income to $5.145 billion, surpassing analyst expectations. 关键产品销售和最近的FDA批准有助于取得这些强的结果. Key product sales and recent FDA approvals contributed to these strong results.